AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03964376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal High Flow
Description: Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute
Study NCT03964376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
Study NCT00376519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
Study NCT00376519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Will be administered beginning on day -3 and adjusted to maintain a level of >200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
Study NCT00914576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% Oxygen
Description: breathing of 100% O2 for 30 minutes on both study days
Study NCT00914576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100% Oxygen
Description: breathing of 100% O2 for 30 minutes on both study days
Study NCT00914576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escherichia coli Endotoxin
Description: Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
Study NCT00914576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escherichia coli Endotoxin
Description: Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
Study NCT02494934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioural therapy
Description: The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
Study NCT02494934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
Study NCT01347658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Description: Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
Study NCT01862393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 400 microseconds
Description: Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
Study NCT01987076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days.
Study NCT01987076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol
Description: Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
Study NCT02363842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure redistribution surface
Description: Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
Study NCT02057731 — intervention group
Intervention type: GENETIC
Intervention: Glycogen Storage Disease markers
Description: Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
Study NCT00376519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m\^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
Study NCT00376519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
Study NCT01862393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 700 microseconds
Description: Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
Study NCT01862393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1000 microseconds
Description: Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
Study NCT00376519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treg cell infusion
Description: On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10\^6/kg, 0.3 x 10\^6/kg, 1 x 10\^6/kg and 3 x 10\^6/kg weight (determined on the day prior to administration of the preparative therapy).
Study NCT00376519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
Study NCT00376519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
Study NCT01366443 — intervention group
Intervention type: PROCEDURE
Intervention: Sterile speculum exam
Description: Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
Study NCT01366443 — intervention group
Intervention type: PROCEDURE
Intervention: ROM Plus Exam
Description: Vaginal swab exam for ROM Plus Test
Study NCT01366443 — intervention group
Intervention type: PROCEDURE
Intervention: Chart Reveiw
Description: Post delivery blinded chart review by expereienced obstetrician
Study NCT04616911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rerouting seton
Description: Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
Study NCT03520816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burn Physiotherapy Protocol
Description: It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
Study NCT00885417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cravit-based sequential therapy
Description: Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
Study NCT04191967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocoagulation
Description: Treatment of positive screening results will be performed using the Liger Thermocoagulator device
Study NCT02815241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-046)
Study NCT00878215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Image Guided System
Study NCT03444272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Daklatasuvir
Description: HCV Treatment (Sofosbuvir and Daklatasuvir)
Study NCT00118378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 50 mg per day, increasing to 200 mg per day as clinically indicated
Study NCT00118378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg per day, increasing to 200 mg per day as clinically indicated
Study NCT01371084 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pedal@Work Worksite Wellness
Description: Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
Study NCT01371084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedal@Work
Description: Worksite wellness program.
Study NCT03351387 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: SPY Intra-operative Angiography
Description: The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
Study NCT05114382 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EP Procedure
Description: Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
Study NCT04616911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: Ligation of the intersphincteric fistula tract
Study NCT01403168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSTEOPATHY + conventional analgesic treatments
Description: 5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment.
Study NCT01403168 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional analgesic treatments
Description: These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD201
Description: Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 via i.v. infusion during cycles 1 to 4.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 via i.v. infusion during cycles 1 to 4.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2 via i.v. infusion during cycles 5-8.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m2 via i.v. infusion during cycles 5-8.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 via i.v. infusion during cycles 5-8.
Study NCT03013504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 500 mg/m2 via i.v. infusion during cycles 5-8.
Study NCT00541333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone Injection
Study NCT00541333 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Copaxone Injection
Study NCT04134078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
Study NCT01275105 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle
Description: one drop in each eye at designated visits
Study NCT01275105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 0.01%
Description: one drop in each eye at designated visits
Study NCT01275105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 0.025%
Description: one drop in each eye at designated visits
Study NCT01275105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline HCl 0.025%
Description: one drop in each eye at designated visits
Study NCT00878215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Passive Tracking
Study NCT00878215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver surgery
Description: -Standard of care
Study NCT00878215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver abalation
Description: -Standard of care
Study NCT02163993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ
Study NCT02163993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study NCT02472691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
Study NCT02472691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
Study NCT02472691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusions
Description: DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10\^6 CD3/kg (1st DLI), 1-5x10\^6 CD3/kg (2nd DLI) and 5-15x10\^6 CD3/kg (3rd DLI).
Study NCT02822534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
Study NCT00992784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine 2186877A
Description: Single dose, intramuscular injection
Study NCT00992784 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: Single dose, intramuscular injection
Study NCT00432094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
Study NCT00432094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
Study NCT00432094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
Study NCT00432094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 225 mg/m\^2 intravenous over 3 hours on Day -7.
Study NCT00432094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: 150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
Study NCT02868268 — intervention group
Intervention type: OTHER
Intervention: Gene panel sequencing of tumor specimens
Description: Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
Study NCT06677177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nano-water, Tamsulosin Dutasteride
Description: Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
Study NCT06677177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular water, tamsulosin, Dutasteride
Description: Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
Study NCT04053816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study NCT01014624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria.
Study NCT01014624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria.
Study NCT00393120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB009471
Description: 100mg SR (sustained release) orally once daily
Study NCT00393120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB009471
Description: 300mg SR (sustained release) orally once daily
Study NCT00393120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Orally once daily
Study NCT00731549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: 300mg or 400mg
Study NCT02191007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol Betamethasone ointment and Calcipotriol ointment
Study NCT02191007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Betamethasone ointment
Study NCT02191007 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Calcipotriol Betamethasone ointment and Urea Cream
Study NCT04428099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change promotion program
Description: The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
Study NCT04428099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfullness based cognitive program
Description: The intervention consists of 8 group sessions with a mindfulness-based cognitive program
Study NCT04428099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Written information about lifestyle change suggestions
Study NCT04428099 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Information
Description: Written information about lifestyle change suggestions